4.6 Article

The DrrAB Efflux System of Streptomyces peucetius Is a Multidrug Transporter of Broad Substrate Specificity

Journal

JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 289, Issue 18, Pages 12633-12646

Publisher

AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.M113.536136

Keywords

ABC Transporter; Anticancer Drug; Drug Resistance; Multidrug Transporters; Protein Drug Interactions; Competitive Inhibition; Drug Binding Sites; Inside-out Membrane Vesicles; Non-competitive Inhibition; Single-drug Transporters

Funding

  1. National Institutes of Health [GM51981-09]

Ask authors/readers for more resources

Background: DrrAB is dedicated to export of doxorubicin in Streptomyces peucetius, an organism that produces this anticancer drug. Whether this prototype system can export other drugs has not been investigated. Results: DrrAB exports multiple drugs efficiently. Conclusion: Substrate specificity of DrrAB overlaps with known bacterial and human multidrug resistance proteins. Significance: This study suggests common mechanisms and origin for DrrAB and other MDR proteins. The soil bacterium Streptomyces peucetius produces two widely used anticancer antibiotics, doxorubicin and daunorubicin. Present within the biosynthesis gene cluster in S. peucetius is the drrAB operon, which codes for a dedicated ABC (ATP binding cassette)-type transporter for the export of these two closely related antibiotics. Because of its dedicated nature, the DrrAB system is believed to belong to the category of single-drug transporters. However, whether it also contains specificity for other known substrates of multidrug transporters has never been tested. In this study we demonstrate under both in vivo and in vitro conditions that the DrrAB system can transport not only doxorubicin but is also able to export two most commonly studied MDR substrates, Hoechst 33342 and ethidium bromide. Moreover, we demonstrate that many other substrates (including verapamil, vinblastine, and rifampicin) of the well studied multidrug transporters inhibit DrrAB-mediated Dox transport with high efficiency, indicating that they are also substrates of the DrrAB pump. Kinetic studies show that inhibition of doxorubicin transport by Hoechst 33342 and rifampicin occurs by a competitive mechanism, whereas verapamil inhibits transport by a non-competitive mechanism, thus suggesting the possibility of more than one drug binding site in the DrrAB system. This is the first in-depth study of a drug resistance system from a producer organism, and it shows that a dedicated efflux system like DrrAB contains specificity for multiple drugs. The significance of these findings in evolution of poly-specificity in drug resistance systems is discussed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available